CervoMed Inc.
Business
CervoMed is a clinical-stage biotechnology company developing neflamapimod, an orally administered small-molecule p38α inhibitor targeting age-related brain disorders. Its lead program addresses dementia with Lewy bodies (DLB) without Alzheimer's disease co-pathology, with Phase 2b data showing statistically significant improvements in cognitive and motor function. The company is also evaluating neflamapimod in frontotemporal dementia (nonfluent variant primary progressive aphasia), recovery after ischemic stroke, and amyotrophic lateral sclerosis through ongoing Phase 2a trials and platform studies. CervoMed has licensed neflamapimod from Vertex and operates primarily in the United States and Europe through clinical research collaborations.
Summary from 10-K filed 2026-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Grant revenue | 4 | 10 | 7 | 0 | — | |
| Research and development | 22 | 19 | 8 | 1 | 8 | |
| General and administrative | 10 | 9 | 7 | 2 | 7 | |
| Total operating expenses | 32 | 28 | 15 | 3 | — | |
| Loss from operations | −28 | −18 | −8 | −3 | −25 | |
| Other expense | −8,327 | −991 | 5 | −2 | — | |
| Interest income | 1 | 2 | 219,430 | 62,226 | — | |
| Total other income, net | 1 | 2 | 6 | −2 | — | |
| Net loss | −27 | −16 | −2 | −6 | −24 | |
| Net loss per share of common stock, basic and diluted (in dollars per share) | −2.98 | −2.02 | −0.82 | −11.2 | −12.38 | |
| Weighted average shares outstanding, basic and diluted (in shares) | 9 | 8 | 3 | 518,140 | — | |
| Net unrealized (loss) gain on marketable securities | −50,381 | 56,197 | 0 | −35,375 | 0 | |
| Total comprehensive loss | −27 | −16 | −2 | −16 | −24 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 9 | 8 | 4 | 37 | |
| Marketable securities | 13 | 30 | 0 | 12 | 0 | |
| Prepaid expenses and other current assets | 1 | 2 | 1 | 64,127 | 510,015 | |
| Deferred offering costs | 300,000 | 0 | — | — | — | |
| Grant receivable | 426,993 | 2 | 915,404 | 0 | — | |
| Total current assets | 23 | 43 | 10 | 4 | 38 | |
| Total assets | 23 | 43 | 10 | 4 | 38 | |
| Accounts payable | 1 | 2 | 662,471 | 97,302 | 947,495 | |
| Accrued expenses and other current liabilities | 3 | 2 | — | — | — | |
| Total current liabilities | 5 | 4 | — | — | 3 | |
| Total liabilities | 5 | 4 | 3 | 13 | 3 | |
| Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively | 9,252 | 8,702 | 5,674 | 518 | 2,038 | |
| Additional paid-in capital | 116 | 110 | 62 | 19 | 165 | |
| Accumulated other comprehensive income | 5,816 | 56,197 | 0 | −35,375 | 0 | |
| Accumulated deficit | −98 | −71 | −54 | −52 | −130 | |
| Total stockholders' equity | 18 | 39 | 7 | −33 | 35 | |
| Total liabilities and stockholders' equity | 23 | 43 | 10 | 4 | 38 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Accretion of discount on marketable securities, net | −854,077 | −1 | — | — | — | |
| Stock-based compensation expense | 1 | 1 | 407,632 | 333,835 | 897,260 | |
| Prepaid expenses and other current assets | 638,355 | −641,089 | −1 | 85,104 | −248,997 | |
| Deferred offering costs | −310,581 | 0 | — | — | — | |
| Accounts payable | −67,322 | 848,969 | 565,169 | 79,154 | — | |
| Accrued expenses and other liabilities | 834,157 | 690,290 | 1 | 215,679 | — | |
| Grant receivable | 2 | −1 | −915,404 | — | — | |
| Net cash used in operating activities | −23 | −17 | −7 | −3 | −15 | |
| Purchase of marketable securities | −25 | −48 | 0 | −38 | 0 | |
| Maturities of marketable securities | 44 | 19 | 0 | 26 | 0 | |
| Net cash provided by (used in) investing activities | 18 | −29 | 0 | −12 | 4,000 | |
| Proceeds from sale of common stock, prefunded warrants and common stock warrants | 0 | 46 | — | — | — | |
| Net cash provided by financing activities | 5 | 46 | 11 | 0 | 33 | |
| Net (decrease) increase in cash and cash equivalents | −764,027 | 1 | 4 | −3 | 19 | |
| Stock options granted in lieu of cash bonus | 0 | 255,724 | — | — | — | |
| Cashless exercise of pre-funded warrants | 0 | 945 | 0 | — | — | |
| Deferred offering costs in accounts payable | 10,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CervoMed Inc.'s CIK number?
CervoMed Inc.'s SEC CIK number is 0001053691 (1053691). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CervoMed Inc.'s SEC filings?
All of CervoMed Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CervoMed Inc. last report earnings?
CervoMed Inc. (CRVO) most recently filed an earnings 8-K with the SEC on May 18, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-017637). This is CervoMed Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CervoMed Inc.'s most recent earnings 8-K?
CervoMed Inc.'s latest earnings 8-K (Item 2.02) was filed May 18, 2026 under accession 0001437749-26-017637. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CervoMed Inc.'s latest earnings 8-K →
Look up any company's CIK number →